Administration of checkpoint inhibitors such as anti-CTLA-4 (Box 1) mAb induces severe colitis in a subset of cancer patients undergoing treatment with this immunotherapeutic antibody (Waldman et al., 2020). This evidence concerns the gene CTLA4 and colitis.